Works on the Bench, Fails in the Field

Clinical diagnostics increasingly require simultaneous detection of multiple biomarkers — for sepsis, cardiac events, cancer screening, and infectious disease panels — from a single sample at the point of care. Laboratory-based multiplexed assays (e.g., Luminex bead arrays, mass spectrometry) can detect dozens of analytes simultaneously, but these require controlled environments, trained technicians, and sample preparation that is incompatible with field or bedside use. Despite two decades of research into miniaturized multiplexed biosensors, no platform reliably detects more than 3-4 analytes simultaneously in unprocessed clinical samples (whole blood, saliva, urine) outside a laboratory setting.

Sepsis kills approximately 350,000 Americans annually, and early detection of its multi-biomarker signature (procalcitonin, lactate, IL-6, C-reactive protein) within the first hour of presentation can reduce mortality by 30-40%. Rapid multi-pathogen detection panels for respiratory illness (COVID, influenza, RSV, bacterial pneumonia) would transform emergency department triage. In low-resource settings, a single multiplexed rapid test could replace multiple individual lateral flow assays, reducing cost and sample volume requirements. The inability to perform multiplexed detection at point-of-need means that diagnostic information arrives too late to guide initial treatment decisions.

Microfluidic lab-on-a-chip devices can integrate multiple detection zones but suffer from cross-reactivity between closely spaced assays, bubble formation that disrupts flow, and clogging from complex biological matrices like whole blood. Electrochemical sensor arrays using functionalized electrodes achieve multiplexing in buffer solutions but experience fouling and signal drift within minutes of exposure to real clinical samples. Paper-based lateral flow assays can be multiplexed to 2-3 analytes but lack quantitative accuracy and dynamic range. Surface-enhanced Raman scattering (SERS) platforms offer molecular fingerprinting but require expensive laser systems and are sensitive to temperature fluctuations. The fundamental challenge is that strategies to increase analytical sensitivity (more surface area, more capture molecules, longer incubation) conflict with strategies needed for rapid, simple, field-robust operation.

A breakthrough in anti-fouling surface chemistry that maintains biorecognition element activity in complex samples for the duration of the assay would address the most persistent failure mode. Alternatively, sample preparation approaches that can separate plasma from whole blood in seconds without external equipment (passive microfluidics, acoustic separation) would make existing multiplexed detection technologies viable. Machine learning approaches to deconvolve overlapping signals from cross-reactive sensor arrays could circumvent the physical separation requirement entirely.

A student team could build a benchtop prototype that combines a simple passive plasma separation membrane with a 4-plex electrochemical detection array, testing it against spiked whole blood samples and comparing performance to laboratory reference methods. Alternatively, a team could develop and validate an ML-based signal deconvolution algorithm for a commercial electrochemical sensor array exposed to mixed analyte solutions. Relevant disciplines include biomedical engineering, analytical chemistry, and machine learning.